MedTrace Logo

Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis

NCT01967199 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2017-02-24

No results posted yet for this study

Summary

The purpose of this study is to establish the safety and effectiveness of paclitaxel eluting balloon (SeQuent Please) compared to coronary stenting with the Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine) in the treatment of drug eluting stent restenosis.

Conditions

  • Coronary Restenosis

Interventions

DEVICE

Everolimus-eluting balloon expandable stent

Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)

DEVICE

paclitaxel eluting balloon

paclitaxel eluting balloon (SeQuent Please)

Sponsors & Collaborators

  • CardioVascular Research Foundation, Korea

    collaborator OTHER

  • Seung-Jung Park

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-18
Primary Completion
2017-02-14
Completion
2017-02-14

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01967199 on ClinicalTrials.gov